

AD_____

AWARD NUMBER: W81XWH-05-1-0434

TITLE: A Polyamine Oxidizing Enzyme as a Drug to Treat Breast Cancer

PRINCIPAL INVESTIGATOR: William S. McIntire, Ph.D.

CONTRACTING ORGANIZATION: Northern California Institute for Research &
Education (NCIRE)
San Francisco, CA 94121

REPORT DATE: July 2009

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 July 2009		2. REPORT TYPE Final		3. DATES COVERED 20 Jun 2005 – 19 Jun 2009	
4. TITLE AND SUBTITLE A Polyamine Oxidizing Enzyme as a Drug to Treat Breast Cancer			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-05-1-0434		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) William S. McIntire, Ph.D. E-Mail: william.mcintire@ucsf.edu			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Northern California Institute for Research & Education (NCIRE) San Francisco, CA 94121			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Work was initiated to test two polyethylene glycolated (PEGylated) forms of bovine serum amine oxidase (SAO) as effective treatments for breast cancer using a mouse model. Hopefully, this approach, or a variation thereof, could be used as a new a therapy for breast and other human cancers. Currently, a large quantity of pure bovine SAO is in hand, which was obtained from ~ 10 gallons of fresh cow blood. A final purification step was used to produce large quantities of extremely pure SAO. Attempts to find a cost-effective, practical method for the deglycosylation of SAO were unsuccessful. Using different PEGylating reagents, we attempted to obtain several PEG derivatives of SAO. Although preliminary test indicated that SAO could be PEGylated at a fairly high level, efforts to repeat this on a large scale failed. Hence, it has not been possible to test any PEG-SAO derivatives in non-tumorigenic mice, or mice harboring human breast-cancer tumors. Effort to find efficient ways to PEGylate SAO at a high level will continue. High level PEGylation occurred with freshly prepared SAO. Although about 3 grams of highly pure enzyme, it is proposed that freshly prepared oxidase is required. In the future, will carry out smaller scale purifications, and only use the freshly prepared SAO for PEGylation, & we will try different PEGylation reagents. Hopefully, the problem can be remedied.					
15. SUBJECT TERMS cancer, tumor, breast cancer treatment, polyamines, serum amine oxidase, plasma amine oxidase, drug design					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER (include area code)
U	U	U	UU	9	

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	8
References.....	8
Appendices.....	9
Supporting Data.....	9
Bibliography of Publications & Meeting Abstracts.....	9
Salaried Employees.....	9

FINAL PROGRESS REPORT (2009)

AWARD NUMBER W81XWH-05-1-0434

INTRODUCTION

The goal of this research was to obtain large quantities of two polyethylene glycolated (PEGylated) forms of bovine serum amine oxidase (SAO) that would be tested as anti-tumor agents in mouse breast cancer models. After injecting PEG-encapsulated SAO into the bloodstream, it would target specifically tumors due to the abnormally large pore in the blood vessels engulfing tumors. PEGylated proteins are known to have a long half-life in the blood and are non-antigenic. Hence, over time, they would accumulate in tumors but not normal tissues (1-3). To prevent the SAO from interfering or substituting for the endogenous murine SAO (i.e., in its role as Vascular Adhesion Protein-1, VAP-1; ref. 4) in the blood, we sought to deglycosylate the bovine SAO before PEGylating. VAP-1 is important for leukocyte migration from the blood into the tissues.

SAO oxidizes efficiently N^1 -acetyl-spermine and N^1 -acetyl-spermidine. These acetylated polyamines are exported from tumor cells at high levels. Presumably, toxic products will be generated locally in sufficient quantities, via the oxidation of the acetylated polyamines by modified SAO, to slow or arrest the growth, or kill tumor cells without harming substantially non-cancerous tissues (1, 2). A recent report indicates that administering PEG-proteins to animals or human poses no significant risk (5).

BODY

TASK 1. Prepare sufficient quantities of two PEG-derivatives of bovine serum amine oxidase (SAO).

A. Purification of bovine serum amine oxidase (SAO). The enzyme was purified using established procedures (6-8). It required nearly two month, full-time for the PI to complete the purification:

Step 1: Processing of bovine blood. Forty Liters (10.6 gal) fresh bovine blood obtained from a local slaughterhouse was immediately treated with 1/10th volume of sodium citrate, and was put on ice for transport to the lab. The serum was centrifuged at 10,000 rpm in 380 mL centrifuge bottles for 30 min to remove cells.

Step 2: (NH₄)₂SO₄ treatment. The resulting red liquid was made 35 % (NH₄)₂SO₄ by slowly adding solid salt to the stirring solution, over 1 h period. Once all the (NH₄)₂SO₄ dissolved, the solution was stirred for another hour, and then centrifuged at 10,000 rpm in 380 mL centrifuge bottles for 30 min. The supernatant was collected, and brought to 55 % (NH₄)₂SO₄ as before. After centrifugation, the resulting pellet, which had the majority of the SAO activity, was redissolved in ~ 1.5 L of 10 mM KP_i, pH 7.0. The liquid was centrifuge to remove insolubles and then concentrated in 350 mL Amicon pressure concentrators using YM30 membranes. Once the volume of the sample reached ~ 50 mL, it was replenished with ~ 300 mL of the buffer. This process was repeated four times. The final volume was brought to 3 L with the 10 mM buffer.

Step 3. DEAE-cellulose ion-exchange chromatography. The sample was applied to a 14 x 35 cm column packed with Watman DEAE-cellulose. The flow rate was about 60 mL/min. The column was washed with 4 L of 10 mM KP_i, pH 7.0 buffer, and the protein was eluted with a 10 L gradient from 0 to 150 mM KCl in the same buffer, followed by 3 L of 10 mM KP_i, pH 7.0 containing 150 mM KCl. Thirty six-mL fractions were collected, and all fraction that had all but a trace of SAO activity were pooled. Assays were done using the procedure described in reference 9 using 5 mM benzylamine as the

substrate. One to ten microliters of each fraction were added to 50 μL of the assay mixture. The development of the red chromophore color was following to determine the relative activities. The pooled-fractions solution was concentrated using two 400-mL Amicon pressure concentrator with YM30 membranes. After concentrating to ~ 100 mL, 250 mL of 100 mM KPi , pH 7.2 was added and the liquid again concentrated to ~ 50 mL. This step was repeated twice more. The final concentration was brought to 100 mL.

Step 4. Concanavalin-A Sepharose 4B affinity chromatography. Fifty milliliters of the solution was applied to a 2.5 x 55 cm column packed with Con-A Sepharose 4B (Sigma). The sample was washed with 100 mM KPi , pH 7.2 buffer until the A_{280} readings of the elutant fell to < 0.05 . The column was then eluted with a 250 mM methyl α -mannopyranoside in 100 mM KPi , pH 7.2 solution. All fractions containing activity were pooled. The 2nd 50 mL portion of the protein sample was processed in the same manner. The pooled fractions were concentrated and washed as above with 250 mM KPi , pH 7.0 buffer. The liquid was brought to 100 mL with this buffer.

Step 5. ULTROGEL AcA 34 molecular sieving chromatography. Half of the sample was applied to a 5 x 95 cm column packed with ULTROGEL AcA 34 resin (BIOSEPPRA) equilibrated with 250 mM KPi , pH 7.0 buffer. The protein was eluted with this buffer at a flow rate of about 30 mL/hour. All fractions containing but a trace of activity were pooled. The 2nd half of the sample was chromatographed in the same manner. At this point, the SAO was fairly pure and it had the expected specific activity (6). The pooled fractions were concentrated, and washed into 100 mM KPi , pH 7.2 buffer containing 100 mM KCl. The concentration was about 30 mg/mL. The enzyme was stored in 10 mL and 1.5 mL fractions at -80 °C. The final yield of SAO was about 3 grams. The specific activity (k_{cat}) was 0.24 $\mu\text{mol}/(\text{min mg})$ ($K_M = 1.7$ mM) (25 mM KPi , $I = 0.075$, pH 7.0, air-saturated buffer, $T = 30$ ° C) using the typical substrate benzylamine. However, we found spermine to be a much better substrate in the same buffer (air saturated, $T = 30$ ° C); $k_{\text{cat}} = 6.6$ $\mu\text{mol}/(\text{min mg})$ & $K_M = 10.1$ μM . For these assay we used the ABTS/Peroxidase assay describe in the literature (10); ABTS is 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid).

Step 6. Macro-Prep Ceramic Hydroxyapatite, Type I chromatography. A column (1.6 x 10 cm; GE Healthcare HR 16/10) was dry packed with Macro-Prep Ceramic Hydroxyapatite, Type I chromatography material (Bio-Rad). The column was washed extensively with degassed 1 M KPi , pH 7.2 buffer to remove absorbed material and fines, and to eliminate all air voids. The column was then washed with 1 mM KPi , pH 7.2 buffer. Just before using, the enzyme solution was exchanged by several concentration/5 mM KPi , pH 7.2 dilution cycles washed using Centricon (Amicon) YM30 centrifuge concentrators. Six hundred microliter of the SAO solution (12.5 mg/mL) was diluted with 1.35 mL water just prior to injecting the entire volume onto the column: flow rate – 3 mL/min; wash 6 min with water, then a linear gradient from 0 to 0.5 M KPi , pH 7.25 buffer in 30 min (Fig. 1yy). PAGE indicated that the SAO was pure, with only a low trace of other proteins.

B . Deglycosylation of bovine SAO. The enzyme has, at least, 3 glycosylated sites (11). The carbohydrate moieties are required for its role as VAP-1 (4). Hence, to minimize side-effects that might occur when inject into teat animals, we attempted to remove the attached carbohydrate to the greatest extent feasible. To accomplish this we used the ProZyme Glyko enzymatic deglycosylation kit. Initially, we tried to deglycosylate 0.1 mg of SAO according to the manufactures instructions. Even after prolonged incubation (2 weeks; recommended 1-5 days), very little deglycosylation occurred as judged by SDS-PAGE (12). Even at 5-time higher deglycosylating enzymes, little deglycosylation occurred after 5 days. It was estimated that it would cost many thousands of dollars to deglycosylate a few milligrams of SAO, and still be too little for our studies. Hence, this endeavor was terminated. This required about 2 months part-time work by the PI.




Figure 1yy. Final step of bovine SAO purification - Macro-Prep Ceramic Hydroxyapatite, Type I chromatography. The flow rate was 3 mL/min. After injecting the sample, the column was washed 6 min with water, and the protein eluted with a linear gradient from 0 to 0.5 M KPi, pH 7.25 buffer in 30 min. The upper chromatogram is a plot of A_{465} vs time, and the lower one is a plot of A_{280} vs time. A_{465} is the approximate maximum absorbance of SAO in the visible region. A SAO-containing fraction, from ~ 15.5 min to ~ 18.2 min, was collected.

C. PEGylation of SAO. Two milligrams of SAO in 1 mL of 50 mM KPi, pH 7.4 at 25 °C was reacted with either 4.7 mg Sunbright ME-050CS (5 kDa PEG) for 1 h, 19 mg Sunbright ME-200CS (20 kDa PEG) for 1 h, or both (1 h, first with 4.7 mg ME-050CM, and then 1 h with ME-200CM). These *N*-hydroxysuccinimide ester derivatives of mPEG (methoxy-PEG) were purchased from NOF, American Corporation, Tokyo, White Plains, NY. They react specifically with the ϵ -amino group of Lys residues. From the structure of SAO, we estimated that there are ~ 13 surface Lys residues/subunit of the homo-dimeric oxidase; the level of PEGylated reagent was added at about a 3.5 molar excess to surface Lys.

We use the TNBS (trinitrobenzene sulfonate) method described in the literature to measure free amino groups of a protein (from Lys and the N-terminal amino acid) of SAO (13). With this method, we found 15.3 free amino groups/subunit for unadulterated SAO, 10.5 free amino groups/subunit for SAO-5 kDa PEG, 11.5 free amino groups/subunit for SAO-20 kDa PEG, and 9.6 free amino groups/subunit for SAO-5/20 kDa PEG. This gives about five 5-kDa PEG groups, about four 20-kDa PEG groups, and about six 5/20-kDa groups per subunit, respectively. We found that SAO treated with both PEGylating reagents lost a significant amount of activity, so it was not studied further. Below are the steady-state kinetic parameters for various forms of SAO. The k_{cat} values decrease slightly, and the K_M values changed modestly for the PEGylated derivatives.

SAO: $k_{cat} = 6.6 \mu\text{mol}/(\text{min mg})$, $K_M = 10.1 \mu\text{M}$

SAO-5 kDa PEG: $k_{\text{cat}} = 6 \mu\text{mol}/(\text{min mg})$, $K_M = 10.7 \mu\text{M}$ (~5 PEG/subunit or 10 PEG/SAO)
SAO-20 kDa PEG: $k_{\text{cat}} = 5.6 \mu\text{mol}/(\text{min mg})$, $K_M = 8.6 \mu\text{M}$ (~4 PEG/subunit or 8 PEG/SAO)

We were encouraged by the result because we got significant PEGylation that did not affect the activity very much.

Several months later, we repeated this work, only to find that we got < 1 PEG group/subunit with either reagent. Another try gave the same results. Hence, we switch to similar PEGylating reagents that also reacts with Lys ϵ -amino groups; mPEG-SPA, 5 kDa and mPEG-SPA, m20 kDa (Nektar Therapeutics, San Carlos, CA; SPA indicates succinimidyl propionate). Earlier, we used these to PEGylate human peroxisomal polyamine oxidase at a high level, with little effect on the kinetic parameters (unpublished work). However, for SAO, again we got < 1 Lys modified/subunit with both reagents. Finally, we tried mPEG-PNPC (*p*-nitrophenylcarbonate-PEG; M-NPC-5K and N-NPC-20K from Laysan Bio., Inc.). We use essentially the same methods as reported in reference 14 to derivatize the free amino groups of SAO. Once again, we obtained SAO with very little PEGylation. This is surprising because it was reported the ~60 % of the surface Lys residues are modified using this procedure (14). Total time for this aspect was about 3-4 months full- and part-time work by the PI.

Our endeavors to obtain high quantities of usable PEG derivative of SAO will continue. We plan to try other PEGylating reagents, including branched PEGylating compounds.

TASK 2. Test the general toxicity of the two PEG-SAO derivatives.

This work requires injecting several non-tumorigenic mice with one PEG-SAO derivative, and injecting another group of mice with the second derivative. Since we have yet to procure any viable PEG-SAO derivative (*Task 1*), we cannot proceed with this phase of the research.

TASK 3. Test each PEG-SAO conjugate as an antitumor agent using mice with implanted human tumors.

This task could only have been initiated if we had prepared a large amount of the two PEGylated forms of bovine SAO (*TASK 1*), and we have tested these in nontumorigenic mice (*TASK 2*).

KEY RESEARCH ACCOMPLISHMENTS

- Procured a large quantity of pure bovine SAO.
- Developed a procedure to obtain extremely pure SAO for deglycosylation and PEGylation.
- Attempted to efficiently and cost-effectively deglycosylate bovine SAO. After 2 months of work, this endeavor was deemed untenable.
- Tried to develop methods to produce two PEGylated derivatives of bovine SAO; one form of SAO would have 5 kDa EG groups attached, and the other form of SAO would have 20 kDa PEG groups attached. Using several PEGylating reagents, we failed to find a procedure that yielded high-level PEGylation of SAO.

REPORTABLE OUTCOMES

The only reportable outcome is that we have obtained the requisite amount of pure bovine SAO for the remainder of our research on this project, and that we are attempting to develop methods to PEGylate the enzyme. There are no publications, abstracts etc. resulting from this research.

CONCLUSION

We conclude that PEGylation works well only with freshly purified SAO. Perhaps, even when stored in frozen solution, this amine oxidase self-oxidizes some or all of the ϵ -amino groups of surface Lys. However, if occurring, this process does not seem to affect the solubility or activity of SAO. In the future, we will only use freshly prepared SAO, and carry out the purification on a smaller scale.

Since we have not yet done any animal work, we cannot report any conclusions. If our hypothesis is correct, the treatment may one day be an effective anticancer therapy for human patients.

REFERENCES

1. Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. *Cancer Res* (2002)62:3138-43.
2. Sawa T Wu J Akaike T Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. *Cancer Res* (2000) 60:666-71.
3. Park, YS. Tumor-directed targeting of liposomes. *Biosci. Reports* (2002) 22:267-81.
4. VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation. Jalkanen S, Salmi M. *Arterioscler Thromb Vasc Biol* (2008) 18-26.
5. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. *Drug Metabol Disposition* (2007) 35:9-16.
6. Janes SM, Klinman JP. An investigation of bovine serum amine oxidase active site stoichiometry: Evidence for an aminotransferase mechanism involving two carbonyl cofactors per enzyme dimer? *Biochemistry* (1991) 30:4599-4605.
7. Ishizaki H, Yasunobu KT. Bovine plasma amine oxidase interactions with concanavalin A in solution and with concanavalin A-Sepharose. *Biochim Biophys Acta* (1980) 11:27-34.
8. Falk MC, Staton AJ, Williams TJ. Heterogeneity of pig plasma amine oxidase: molecular and catalytic properties of chromatographically isolated forms. *Biochemistry* (1983) 22:3746-51.
9. Holt A, Sharman DF, Baker GB, Palcic MM. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. *Anal Biochem* (1997) 15:384-92.
10. McCoy-Messer, J, Bateman RC. Instability of the ABTS/peroxidase reaction product in biological buffers. *Biotechniques* (1993) 15:270-3.
11. Lunelli M, Maria Di Paolo ML, Biadene M, Calderone V, Battistutta, R, Scarpa M, Rigo A, Zanotti G. Crystal structure of amine oxidase from bovine serum. *J Mol Biol* (2005) 346:991–1004.
12. Calderone V, Di Paolo ML, Trabucco M, Biadene M, Battistutta R, Rigo A, Zanotti G. Crystallization and preliminary X-ray data of amine oxidase from bovine serum. *Acta Crystallographica, Section D* (2003). D59, 727±729.
13. Fields, R. The measurement of amino groups in proteins and peptides. *Biochem J* (1971) 124:581-90.

14. Demers N, Agostinelli E, Averill-Bates DA, Fortier G. Immobilization of native and poly(ethylene glycol)-treated ('PEGylated') bovine serum amine oxidase into a biocompatible hydrogel. *Biotechnol Appl Biochem* (2001) 33:201-7.

APPENDICE

NONE

SUPPORTING DATA

NONE

BIBLIOGRAPHY OF PUBLICATIONS & MEETING ABSTRACTS

NONE

SALARIED EMPLOYEES

Dr. William S. McIntire